Meglumine antimoniate

Meglumine antimoniate
Clinical data
AHFS/Drugs.com Micromedex Detailed Consumer Information
ATC code P01CB01 (WHO) QP51AB01 (WHO)
Identifiers
CAS Number 133-51-7 N
PubChem (CID) 64953
ChemSpider 58479 YesY
UNII 75G4TW236W N
ChEMBL CHEMBL239129 YesY
NIAID ChemDB 008733
ECHA InfoCard 100.004.645
Chemical and physical data
Formula Variable
Molar mass Variable
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis.[1] It is manufactured by Aventis[2] and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.

See also

References

  1. Soto, J.; Fuya, P.; Herrera, R.; Berman, J. (1998). "Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study". Clinical Infectious Diseases. 26 (1): 56–58. doi:10.1086/516267. PMID 9455509.
  2. Aventis press release, 15 April 2005. (German)


This article is issued from Wikipedia - version of the 9/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.